Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | LPL | P06858 | 3/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442542 | 0.92 | DGAT1 (0.33) | F2RL1IRAK4DGAT1LPLLIPG | |
| SCHEMBL1440509 | 0.90 | DGAT1 (0.38) | F2RL1IRAK4DGAT1LPLLIPG | |
| SCHEMBL10276614 | 0.86 | LPL (0.40) | F2RL1DGAT1LPLLIPGSNCA | |
| SCHEMBL16283835 | 0.81 | PRMT5 (0.32) | DGAT1CA1CA2CA9 | |
| SCHEMBL1440712 | 0.80 | F2RL1 (0.36) | F2RL1DGAT1LPLLIPG | |
| SCHEMBL1440522 | 0.80 | F2RL1 (0.33) | F2RL1DGAT1 | |
| SCHEMBL1441281 | 0.79 | DGAT1 (0.46) | F2RL1DGAT1 | |
| SCHEMBL1442282 | 0.78 | DGAT1 (0.32) | IRAK4DGAT1LPLLIPGHIF1A | |
| SCHEMBL10276963 | 0.78 | F2RL1 (0.32) | F2RL1 | |
| SCHEMBL1444504 | 0.76 | F2RL1 (0.37) | F2RL1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | F2RL1 3780/4885IRAK4 2469/4885DGAT1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.